BGE-175
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Mar 18, 2021 → May 19, 2022
NCT ID
NCT04705597About BGE-175
BGE-175 is a phase 2 stage product being developed by BioAge Labs for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04705597. Target conditions include Covid19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04705597 | Phase 2 | Terminated |
Competing Products
20 competing products in Covid19